Sevirumab
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CMV |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
| (verify) | |
References
- Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; et al. (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- ClinicalTrials.gov
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.